INCY

Incyte Corporation

Incyte Corp is a biopharmaceutical company. It discovers, develops and commercializes proprietary therapeutics. Its product JAKAFI, a JAK1 and JAK2 inhibitor is used for treatment of patients with intermediate or high risk myelofibrosis.

Incyte Corporation (INCY) is scored daily on Deltasharpe Prism against Healthcare sector peers across five pillars: Value, Growth, Profitability, Momentum and Revisions.

Quantitative Factor Evaluation • Updated

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Historical Factor Score Progression

Date Value Growth Profitability Momentum Revisions Overall
2026-11-16 C+ (2.6) B- (3.1) B (3.4) B (3.2) B (3.3) B- (3.1)
2026-11-09 C+ (2.7) B- (3.1) B (3.4) B (3.2) B (3.3) B- (3.1)
2026-11-02 C+ (2.6) B- (3.1) B (3.4) B (3.4) B (3.3) B (3.2)
2026-10-31 B (3.2) B (3.2) B (3.5) B (3.2) C+ (2.5) B- (3.1)
2026-10-30 B (3.2) B (3.2) B (3.5) B (3.2) C- (2.1) B- (3.0)
Page 1 of 2

Showing the last month only. Subscribe for the full factor score history.

For more — Subscribe